

Proposed Project Scope

Nab-paclitaxel for Hypersensitivity Reactions to Taxanes

Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of nab-paclitaxel for hypersensitivity reactions to taxanes.

Table I: Policy Questions

Item	Policy Question
1	Should nab-paclitaxel be publicly reimbursed for hypersensitivity reactions to taxanes?

Table II: Products Available in Canada

Product	Manufacturer
Nab-paclitaxel	Celgene Inc.

Project Description

Table III: Project Scope

Criteria	Description
Population	Patients who developed hypersensitivity reactions (HSRs) or infusion-related reactions to taxanes (paclitaxel or docetaxel)
Intervention(s)	Nab-paclitaxel
Comparators	Drug desensitization; docetaxel (if HSR was caused by paclitaxel)
Outcomes	Response rate, adverse events

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of nab-paclitaxel for hypersensitivity reactions to taxanes?
2	What are the harms associated with nab-paclitaxel for hypersensitivity reactions to taxanes?
3	What is the expected cost of nab-paclitaxel for hypersensitivity reactions to taxanes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.